Weight loss may be greater with higher-dose GLP-1 agonists, but as with all anti-obesity medication, the cost is substantial, particularly as sustained use may be required to prevent weight regain. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.